First peer-reviewed article with demonstrated efficacy in preclinical and clinical studies  Outlines ability of MagnetOs to deliver uniform, stable and reliable bone fusions Schlieren (Zurich), Switzerland, 22, 2021 - Kuros Biosciences (SIX: KURN) today announced the publication of new data in eCM Journal, a peer-reviewed publication focusing on p [ … ]

Schlieren (Zurich), Switzerland, 17 June, 2021 - Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies and a pioneer in the emerging field of osteoimmunology, today announced that high-profile surgeons will present on the STRUCTURE clinical trial with Fibrin-PTH and on preclinical and clinical data for MagnetOs bone gra [ … ]

MagnetOs U.S. Q1 sales accelerate, rising 117% over Q1 2020 European distribution network expansion ahead of schedule Key commercial events in Australia, UK Schlieren (Zurich), Switzerland, June 2, 2021 - Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies, today pro-vided an update on its commercial activities, wit [ … ]

*    Milestone triggered by Checkmate's initiation of potential registration trial of vidutolimod (CMP-001) in      patients with anti-PD-1 refractory advanced melanoma *    Kuros stands to receive up to $49 million additional milestones plus royalties on sales Schlieren (Zurich), Switzerland, May 17, 2021 - Kuros Biosciences ('Kuros'), a leader in [ … ]

Grant of European patent entitled 'Pharmaceutical Formulation for Use in Spinal Fusion' Schlieren (Zurich), Switzerland, May 5, 2021 - Kuros Biosciences AG (SIX: KURN), a leader in next generation bone graft technologies, today announced that its subsidiary, Kuros Biosurgery AG, has been granted European patent EP 2686027, entitled 'Pharmaceutical  [ … ]